Gdnf, its binding receptor Gfrα1 or its main signaling receptor Ret die after birth mainly as a result of the lack of kidneys, but with intact catecholamine system, rendering postnatal analysis impossible 4 . However, conditional ablation using a loxP-Cre system (referred to as floxed) of GDNF main signaling receptor Ret and Gdnf have yielded conflicting results. Jain et al. reported that Ret deletion from dopamine neurons using DAT-Cre has no effect on brain dopamine system until 9 months of age, when the study was concluded 5 . An independent study by Kramer et al. using a de novo generated loxP-flanked Neurotrophic factors hold promise as therapeutic tools to treat neurodegenerative diseases. GDNF was identified for its ability to support and maintain the midbrain dopamine and noradrenaline neurons 1, 2 , which are specifically affected in Parkinson's disease 3 . Clinical trials to treat Parkinson's disease using GDNF or its family member neurturin (NRTN) have yielded promising, yet conflicting, results 3 . Improvement of therapeutic strategies requires substantial understanding of the physiological role of endogenous GDNF in the maintenance of brain catecholamine system in adult life. Knockout mice for To the Editor: Glial cell line-derived neurotrophic factor (GDNF) has been tested in clinical trials to treat Parkinson's disease with promising, but variable, results. Improvement of therapeutic effectiveness requires solid understanding of the physiological role of GDNF in the maintenance of the adult brain catecholamine system. However, existing data on this issue is contradictory. Using three complementary approaches, we found that, independent of the time of reduction, Gdnf is not required for maintenance of catecholaminergic neurons in adult mice.
GdnF is not required for catecholaminergic neuron survival in vivo
Nestin-Cre (h) Representative TH + immunostaining of coronal midbrain slices at 19 months of age. C, control containing both wild-type and floxed alleles; n = number of animals analyzed in each experiment, n.a. = not applicable, *P > 0.05 or ***P < 0.001 relative to Gdnf C/C , ## P > 0.01 or ### P < 0.001 relative to Gdnf wt/KO . Error bars represent mean ± s.e.m. npg co r r e s p o n d e n c e heterozygous Gdnf F/KO mice were analyzed (Fig. 1d) . Morphological analysis of the catecholamine system using immunostaining for tyrosine hydroxylase, stereological quantification of tyrosine hydroxylase-expressing cells in the midbrain, and optical density (OD) measurements of dorsal striatum (dSTR) and ventral striatum (vSTR) reflecting density of catecholaminergic innervation revealed no difference between the genotypes at 3, 14 and 19 months of age ( Fig. 1f-h ). Locus coeruleus appeared morphologically normal at 19 months of age ( Supplementary Fig. 1d ). Analysis of motor function with open field and rotarod tests revealed no difference in young (2 months) and old (12 months) mice (Supplementary Table 1 ). Given that dopamine system dysfunction is involved in schizophrenia and anxiety, mice were analyzed with pre-pulse inhibition, light-dark and elevated plus-maze tests at both ages. No differences between the genotypes were found (Supplementary Table 1 ).
Next, we tested whether the absence of GDNF is compensated during development by deleting Gdnf in adult animals. Mice were unilaterally striatally injected with AAV5-Cre strategy as Pascual et al. 7 in that we flanked Gdnf exon three encoding for GDNF protein with loxP sites (Fig. 1a) . We studied the effect of Gdnf deletion on the catecholamine system with a focus on the dopamine system using three different gene deletion methods: NestinCre, AAV5-Cre and Esr1-Cre. Nestin-Cre deletes Gdnf from the CNS during embryonic development, whereas intrastriatal injection of adeno-associated virus (AAV) encoding for Cre deletes Gdnf from the innervation target of SN dopamine neurons in adult mice. Finally, we used the same tamoxifen-inducible Esr1-Cre mouse line and experimental procedures as Pascual et al. 7 to replicate their experiments. Gdnf floxed (Gdnf F/F ) mice were generated, genotyped and validated using routine methods (Fig. 1a and Supplementary  Methods, Supplementary Figs. 1a,b and 3 , and Supplementary Methods Checklist). Nestin-Cre mice were analyzed as indicated in Figure 1b . Gdnf mRNA expression from Gdnf wt and Gdnf F alleles was comparable (Fig. 1c) . As expected from earlier work 6, 8 , cross to Nestin-Cre resulted in CNS-specific Gdnf ablation (Fig. 1d,e and Supplementary  Fig. 1b,c) . As in Pascual et al. 7 
, compound
Ret allele revealed that the absence of Ret, either ubiquitously in CNS or in the dopamine neurons using Nestin-Cre or DAT-Cre, respectively, results in modest, age-dependent dopamine system degeneration in substantia nigra (SN), but not in ventral tegmental area (VTA) or noradrenergic locus coeruleus, starting around 12 months of age 6 . In contrast with the above studies, Pascual et al. reported that ubiquitous GDNF reduction in 2-month-old adult mice using a tamoxifen/ Esr1-Cre system resulted in marked degeneration of dopamine neurons in both SN and VTA, and a complete degenerative destruction of locus coeruleus 7 months after tamoxifen injection 7 . The existence of alternative GDNF receptors, NCAM and Syndecan-3, and/or onset of developmental compensation in Ret floxed mice have been suggested to explain the apparent discrepancy. However, given the obvious clinical relevance of GDNF and the lack of follow-up studies on GDNF conditional deletion since Pascual et al.'s report 7 in 2008, the above inconsistency has remained a matter of intensive debate.
Here we report de novo generation and analysis of Gdnf floxed mice. We used the same co r r e s p o n d e n c e on rotational behavior in either laboratory (Fig. 2d-g and Supplementary Fig. 2d-g ), no effect on catecholaminergic cell survival in SN ( Fig. 2h and Supplementary Fig. 2h ) and no effect on striatal tissue dopamine (Fig. 2i) or its metabolite levels ( Supplementary  Fig. 2i,j) . Finally, we repeated the experiments reported by Pascual et al. 7 using the same Esr1-Cre line and experimental conditions (Fig. 3a) . At 2 months of age, Gdnf mRNA levels in separate stock of the virus to confirm the acute reduction in striatal GDNF. In this batch, we detected a 40% drop in GDNF protein levels accompanied by a 30% reduction in Gdnf mRNA 30 d post injection ( Supplementary  Fig. 2b,c) . Unilateral decline in dopamine system function is associated with side bias in corridor test 9, 10 and by amphetamine (ipsilateral) or apomorphine (contralateral) induced rotational bias 11 . During the 7 month followup, unilateral GDNF reduction had no effect (Supplementary Fig. 2a ) and analyzed as indicated in Figure 2a . To strengthen the conclusions, we performed behavioral experiments in parallel in two independent laboratories, Lund University and the University of Helsinki. Analysis of striatal Gdnf mRNA levels revealed a fivefold reduction at 1 month and an almost complete ablation at 9 months post AAV5-Cre injection (Fig. 2b,c) . We later measured Gdnf mRNA and GDNF protein levels using a separate batch of animals and a 1 and mixed 129Ola/ICR/C57bl6 in Kopra et al. 2 ). Third, the final model employed by Kopra et al. 2 was the intrastriatal injection of AAV5-Cre in F/F mice (with two floxed Gdnf alleles. The reported efficiency of Gdnf deletion (measured as Gdnf mRNA in the entire striatum 30 d after AAV5 treatment) was highly variable (between 20 and 80% of the control value) and the amount of striatal GDNF protein was maintained above 50% of the normal level. Hence, one could argue that GDNF content was not sufficiently reduced to elicit neurodegeneration in these mice with a mixed genetic background, and that they might be more resistant to GDNF deficiency than other strains. In addition, the possibility that tissue damage produced by stereotaxic AAV injections could have activated glial cells to produce trophic factors that compensate for the lack of GDNF cannot be ruled out 6 . 
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